{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:00:44Z","timestamp":1769583644539,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bbmt.2017.02.012","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:32:36Z","timestamp":1487327556000},"page":"938-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-1594","authenticated-orcid":false,"given":"Toshihiro","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Henzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.02.012_bib0010","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0020","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJM199401133300204","article-title":"Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia","volume":"330","author":"Porter","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0030","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.clml.2015.10.004","article-title":"Donor lymphocyte infusion in hematologic malignancies\u2014good to be fresh?","volume":"16","author":"Hossain","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0045","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bmt.2015.288","article-title":"New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT","volume":"51","author":"Chang","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0050","first-page":"269","article-title":"Second HLA-identical sibling transplants for leukemia recurrence","volume":"9","author":"Mrsic","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0055","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","article-title":"Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens","volume":"11","author":"Radich","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/CCO.0b013e32834bb88e","article-title":"Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma","volume":"23","author":"van Besien","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0065","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12185-012-1056-3","article-title":"Successful treatment by donor lymphocyte infusion of adult T-cell leukemia\/lymphoma relapse following allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Kamimura","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/imt.13.31","article-title":"Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies","volume":"5","author":"El-Jurdi","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0075","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3109\/10428194.2012.656635","article-title":"Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bmt.2016.250","article-title":"Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients","volume":"52","author":"Oostvogels","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0085","first-page":"1214","article-title":"Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions","volume":"95","author":"Porter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.blre.2012.11.002","article-title":"Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?","volume":"27","author":"Chang","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","article-title":"Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"106","author":"Wassmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0110","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0115","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Caocci","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clml.2016.04.017","article-title":"Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia?","volume":"16","author":"DeFilipp","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bmt.2008.259","article-title":"Donor lymphocyte infusions: the long and winding road: how should it be traveled?","volume":"42","author":"Tomblyn","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2017.02.012_bib0135","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2008.103","article-title":"The Japan Marrow Donor Program, the Japan Cord Blood Bank Network and the Asia Blood and Marrow Transplant Registry","volume":"42","author":"Kodera","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0140","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bmt.1702027","article-title":"Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia","volume":"24","author":"Kodera","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/sj.bmt.1702596","article-title":"Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome","volume":"26","author":"Shiobara","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0150","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"Takami","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbmt.2014.10.015","article-title":"Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation","volume":"21","author":"Kanda","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0160","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/asheducation-2014.1.570","article-title":"Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions","volume":"2014","author":"Nikiforow","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0165","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0170","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/bmt.2015.315","article-title":"Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality","volume":"51","author":"Inoue","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0175","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/bmt.2012.268","article-title":"Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia\/lymphoma after umbilical cord blood transplantation","volume":"48","author":"Ito","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12185-009-0370-x","article-title":"Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease","volume":"90","author":"Teshima","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0185","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ctrv.2009.07.004","article-title":"Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects","volume":"35","author":"Ratanatharathorn","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0190","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-016-0281-2","article-title":"Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease","volume":"9","author":"Fransolet","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbmt.2015.10.001","article-title":"Acute graft-versus-host disease: novel biological insights","volume":"22","author":"Teshima","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0210","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0215","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0220","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0225","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/bmt.2013.219","article-title":"A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma","volume":"49","author":"Bensinger","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0230","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0235","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.02.012_bib0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12185-015-1801-5","article-title":"Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Hashimoto","year":"2015","journal-title":"Int J Hematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117302811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117302811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:58Z","timestamp":1761058678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117302811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1083879117302811"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}